Effect of tranexamic acid on the prognosis of patients with traumatic brain injury undergoing craniotomy: study protocol for a randomised controlled trial
Autor: | Hongli Yue, Jie Wang, Yun Yu, Yingzi Chong, Weihua Cui, Yu Lu, Bei Wu |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Antifibrinolytic medicine.drug_class Traumatic brain injury medicine.medical_treatment education law.invention Anaesthesia Randomized controlled trial law Brain Injuries Traumatic Humans Medicine neurosurgery Adverse effect Craniotomy Randomized Controlled Trials as Topic business.industry bleeding disorders & coagulopathies General Medicine Perioperative Prognosis medicine.disease Antifibrinolytic Agents neurological injury anaesthesia in neurology Tranexamic Acid Emergency medicine Neurosurgery business Tranexamic acid medicine.drug |
Zdroj: | BMJ Open BMJ Open, Vol 11, Iss 11 (2021) |
ISSN: | 2044-6055 |
Popis: | IntroductionAbnormal coagulation function aggravates the prognosis of patients with traumatic brain injury (TBI). It was reported that the antifibrinolytic drug tranexamic acid (TXA) could reduce intracranial haemorrhage and mortality in non-operative patients with TBI. However, there is a lack of evaluation of TXA in patients with TBI undergoing craniotomy.Methods and analysisThis is a single-centre randomised controlled, double-blind, parallel study aiming to investigate the effectiveness and safety of TXA in patients with TBI during the perioperative period. Blood loss and transfusion, neurological function, adverse events, mortality and serum immune-inflammatory cytokines will be collected and analysed.Ethics and disseminationEthical approval has been granted by the Medical Ethics Committee of Beijing Tian Tan Hospital, Capital Medical University (reference number KY 2020-136-03). The results of this study will be disseminated through presentations at scientific conferences and publication in peer-reviewed journals.Trial registration numberChiCTR2100041911. |
Databáze: | OpenAIRE |
Externí odkaz: |